top of page

New Alzheimer's Drug ANAVEX 2-73: A Phase 2a Study, Clinical Safety, and Tolerability

  • Writer: ANAVEX® Life Sciences Corp.
    ANAVEX® Life Sciences Corp.
  • Jan 11, 2016
  • 1 min read

Alzheimer’s Association International Conference 2016, Toronto, Canada

Steve Macfarlane, Marco Cecchi, Dennis Moore, Paul Maruff, Kristina M. Capiak, Anastasios Zografidis, Christopher U. Missling


 
 
bottom of page